Project Grant HT94252310832

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $667,485 to the University of California, San Diego to conduct a longitudinal study investigating the mechanisms underlying radiation-induced neurocognitive decline in patients with glioma. The study aims to: 1) Characterize neurocognitive heterogeneity and identify cognitive phenotypes in glioma patients before and after radiation therapy (RT); 2) Analyze biomarkers of...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $926,389 to Wake Forest University Health Sciences (WFUHS) to conduct a clinical PET imaging study using the radiotracer [11C]MPC-6827 to evaluate microtubule integrity as an early biomarker of Alzheimer's disease progression. The study will enroll 75 participants, including cognitively normal adults, cognitively normal adults with positive amyloid PET scans, and adults with mild...

The federal Project Grant award R01CA275767, funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports a research project to characterize synaptic density changes in the brain following radiation therapy. The $1,474,236 award, with a project period of Sep 2024 to Aug 2028, will utilize a novel PET tracer to quantify synaptic density changes in rodent models of both normal brain and brain tumors receiving targeted radiation...

This $15,782,145 Project Grant awarded by the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), will establish the Progressive Supranuclear Palsy (PSP) Clinical Trial Platform (PTP). The PTP will conduct a 12-month randomized, placebo-controlled, Phase 2 platform trial to simultaneously test at least three different tau-related or neuroprotective therapies in 440 participants with mild-to-moderate PSP across approximately 50 North American sites....

The National Cancer Institute (NCI) awarded a $596,095 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Washington. The grant will support the development and validation of the Personalized Remote Radiation Tracking Portable Organ Dosimetry Device (PRRT PODD), a patient-friendly technology that enables personalization of 177Lu-DOTATATE therapy for neuroendocrine tumor patients. The project aims to design compact imaging detectors and software tools for...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $662,096 to the Beckman Research Institute of the City of Hope to conduct research on improving treatment outcomes for locally advanced rectal cancer (LARC). The key objectives are: Determine the safety and efficacy of combining the mitochondrial inhibitor papaverine with short-course radiation therapy to sensitize LARC tumors to radiation. This will involve a Phase I clinical trial...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $676,567 to The Regents of the University of California, San Francisco to conduct preclinical research on a novel radiopharmaceutical therapy (RPT) targeting the transforming growth factor beta (TGFβ) pathway for the treatment of multiple cancer types. The key objectives are to: 1) radiolabel a TGFβ-neutralizing antibody with an imaging isotope (89Zr) and a therapeutic isotope...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $238,500.00 to the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic to treat Alzheimer's disease. The project aims to create a PMO that can efficiently escape endosomes and selectively target the amyloid precursor...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...